I wonder if ficm as a formal group representing can have a say?
11.03.2026 16:58
👍 1
🔁 0
💬 0
📌 0
I wonder if ficm as a formal group representing can have a say?
www.weightmans.com/media-centre...
This ruling is just a lot to unpack. 😨
@ficm.bsky.social is here on Bluesky. 👏🏽👏🏽👏🏽Give a follow iCM people ! :)
Proud to be part of this ! Excellent work from the team.
www.kcl.ac.uk/news/securin...
Very sadly Seshagiri Mallampati, the anesthesiologist who devised the Mallampati score, die two weeks ago. He only retired in 2017, 49 years after he began clinical practice.
litfl.com/seshagiri-ra...
This is basically my villain origin story.
"How old are you?" (unique responses)
OpenSAFELY is open from today! Huge thanks to all who supported this vast collaboration: whole population GP data; in a productive platform; innovative privacy protections; unprecedented support from professions, privacy campaigners; &c
Now it's over to users!
www.bennett.ox.ac.uk/blog/2026/02...
Sending u best energy. Partner got morning sickness for months … one of the worst thing she said. And there’s nothing “morning” about morning sickness either .. (the misnomer!!) May all beings be nausea free 🙏
3/7!! 🙏
That’s how I feel too. With my nice cup of coffee !
I did phem at a great place for elective. Admire the skillset and teams and the review mechanisms but solidifies my approach for hospital based.
Proud to have graduated at this venue @ficm.bsky.social and didn’t realise its history ! youtube.com/shorts/VqtA9...
🎥 Maximizing donor pool: #ECMO driven advances in #transplantation: ELSO & @ishlt.bsky.social #ELSO2025 session
🧠 diagnosing BD in #ECLS
🚑 #ECPR to organ donation
⚙️ #NRP and MP in cardiothoracic #Tx
⚖️ ethical dilemmas of #ECLS, DCD, NRP
🫁🫀 DCD for pediatric recipients
🔗 bit.ly/ELSO2025virtual
Go Arthur!
@kamranabbasi.bsky.social shines with this scathing editorial on the mess that has been made with locally employed Doctors (LEDs) in the U.K.
www.bmj.com/content/391/...
Hope ya like it ! And then the yes minister :)
I do both but lately more python. Agree with article. Python advantage is that for productionising & abstracting away a lot - then the OOP & its design patterns make it much much easier: article alludes to it with DL & MLOps productionise PyTorch. But R for win if doing mixed effect models.
Textbook page with same quote
Firstly, do no (net) harm.
~ (adapted from) Hippocrates
Reading Hunink et al (2014) this morning…
🧐
So a recent Veritasium video on natural selection explains kin selection and does the unavoidable thing of saying that a parent shares "half of its genes with the child". This is wrong, because for any 2 humans, we share almost all of our genes. We share more than 95% with chimpanzees ffs. >>
This honestly should be required reading for anyone undertaking (or evaluating) exploratory studies... ⬇️👍 (It's proper funny too 😅)
NEW paper "Clinical prediction models using machine learning in oncology: challenges and recommendations"
--> tinyurl.com/2h2mcy5h
#machinelearning #prediction #statssky #MLsky #methodsmatter
Cool cake
Whisky is so apt
We talk about SDd every few years don’t we and my experience is that even in its heyday .. in my uk practice .. never get enough buy in from micro to do it and become a thing.
As in why mortality is such a high end point or whether it should be used as threshold?
Which reminds me of this old classic on the Noise Miners.
“'Noise mining is a funny thing,' he said. 'When you first see a bit of noise, it doesn’t look so impressive. But as you work it out of the rock, it gets more and more refined.' This process, he explained, is called 'shucking.'"
Remembering the most likely mediator of reduced mortality in the original EGDT therapy was the presence of the CI in the intervention arm, the regular attendance of an interested and informed clinician (and skilled ICU nurse) likely has a bigger impact than any single drug or intervention.
I don’t understand why we are seeing a temporal effect with results. May be other things are changing ?!
An editorial from JAMA titled "Sodium Bicarbonate in Severe Acidemia and Acute Kidney Injury—Turning the Tide or Chasing a Myth?" by Prit Kusirisin et al., published online October 29, 2025.
💬 Editorial: The BICARICU-2 trial finds IV sodium bicarbonate may delay or reduce kidney replacement therapy in #criticallyill patients with severe #acidemia and #AKI, but its effect on mortality remains uncertain.
#LIVES2025 @esicm.bsky.social
ja.ma/47NwK8E
